Progression-free survival and OS in the antibiotic treatment group were significantly shortened in advanced NSCLC, RCC, and urothelium carcinoma treated with PD-1/PD-L1 monoclonal antibody-based biotherapeutics [80]. This evidence concerns the gene CD274 and renal cell adenocarcinoma.